Bayer Corporation v. Union Of India And Others

For founders and IP professionals, few legal battles illustrate the tension between patent rights and public access to medicine as sharply as a compulsory license dispute. When a government grants a third party the right to produce a patented drug without the inventor's consent, the boundaries of that permission become a high-stakes question. Bayer Corporation's clash with Nacto Pharma Ltd. over the export of a cancer drug called 'Sorafenat' is a textbook example of how a single clause in a compulsory license can trigger a courtroom war.

Bayer Corporation, a global pharmaceutical company, held patent rights over a drug marketed as Sorafenat. Under Section 84 of the Patents Act, 1970, the Controller of Patents had earlier granted a compulsory license to Nacto Pharma Ltd. (NPL), allowing it to manufacture the drug in India under specific conditions. The dispute arose when NPL sought—and obtained—an order permitting it to export Sorafenat outside India for the purpose of conducting clinical trials. Bayer, alarmed that its patented product was being shipped abroad by a licensee it never voluntarily authorized, challenged this move. Bayer contended that exporting the drug fell outside the scope of the compulsory license originally granted, and that the permission to export violated the terms and conditions attached to that license.

Bayer's central argument was straightforward: a compulsory license under Section 84 comes with defined boundaries, and exporting the drug for clinical trials abroad was not part of the deal. From Bayer's perspective, allowing NPL to ship Sorafenat overseas effectively extended the compulsory license beyond what was legally permissible, undermining Bayer's exclusive patent rights in foreign markets. Nacto Pharma, on the other hand, stood by the order permitting export, presumably arguing that clinical trial exports were a legitimate and necessary step in bringing the drug to broader markets. The legal friction centered on a single but powerful question: does a compulsory license granted for manufacture and sale in India automatically authorize export activities, or must such export rights be explicitly granted under Section 107-A of the Patents Act?

Rather than delivering a final ruling on the merits of Bayer's appeal, the court took a procedural but pragmatic approach. It directed that the underlying writ petition be disposed of expeditiously, with instructions to implead the relevant regulatory authorities who had a stake in the export decision. By remanding the matter, the court acknowledged that the question of whether NPL could export Sorafenat under its compulsory license required the participation of regulators who could speak to the conditions imposed by the licensing authority. The court implicitly recognized that the scope and limitations of the compulsory license—particularly the export angle under Section 107-A—had to be examined in light of the specific terms originally attached to the license.

For founders, startup leaders, and IP professionals, this case delivers a clear and practical lesson: the scope of a compulsory license is not a blank check. If your business relies on—or competes with—a compulsory licensee, you must scrutinize the exact conditions imposed by the licensing authority, especially when export rights under Section 107-A come into play. Conversely, if you are operating under a compulsory license, do not assume that domestic manufacturing rights translate into international freedom of movement. Always map the boundaries of your license before shipping product across borders, and engage the relevant regulatory authorities early to avoid costly courtroom detours.